Ti-Based nanoMOF as an Efficient Oral Therapeutic Agent
Source abstract
Abstract
Despite the interest in (Zn, Fe, and Zr)-nanoscaled metal-organic frameworks (nanoMOFs) as intravenous drug nanocarriers, their most convenient oral administration has been almost unexplored. In this scenario, an uncharted Ti-nanoMOF is originally proposed here as an oral therapeutic agent, not as a drug delivery system but as an innovative and efficient oral detoxifying agent of the challenge and timeliness salicylate intoxication (e.g., aspirin). Thus, this orally robust and biosafe Ti-nanoMOF is the only porous nanomaterial, among the six tested MOFs, able to adsorb and retain aspirin under the whole gastrointestinal tract, overpassing the capabilities of the current treatment (i.e., activated charcoal). Further, the biodistribution and bioremoval of Ti-nanoMOF have been assessed, proving a bioprotective character with an intact and almost complete removal by feces.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Curcumin's Biomedical Applications · Adsorption and biosorption for pollutant removal
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
IMDEA Energy, Av. Ramón de la Sagra 3, 28935 Móstoles-Madrid, Spain
Institut Lavoisier, CNRS UMR 8180, UVSQ, Université Paris-Saclay, 45, Avenue Des Etats Unis, 78035 Versailles Cedex, France
Funding
H2020 Marie Sklodowska-Curie Actions · IMDEA Energy Foundation · Ram?n y Cajal · Regional Madrid Funding
References (47)
Show source-provided references
1. 10.1038/4624810.1038/46248 ↗
2. 10.1039/c4cs00094c10.1039/c4cs00094c ↗
3. 10.1038/natrevmats.2017.4510.1038/natrevmats.2017.45 ↗
4. 10.1016/j.ccr.2015.08.00810.1016/j.ccr.2015.08.008 ↗
5. 10.1002/adma.20170736510.1002/adma.201707365 ↗
6. 10.1021/acs.accounts.7b0009010.1021/acs.accounts.7b00090 ↗
7. 10.1016/j.biopha.2013.06.00310.1016/j.biopha.2013.06.003 ↗
8. 10.1021/acs.molpharmaceut.7b0016810.1021/acs.molpharmaceut.7b00168 ↗
9. 10.1002/chem.20160364710.1002/chem.201603647 ↗
10. 10.1039/c7cc03471g10.1039/c7cc03471g ↗
11. 10.3390/ma304248310.3390/ma3042483 ↗
12. https://wonder.cdc.gov/, accessed 01/05/19.
13. http://www.emcdda.europa.eu/publications/edr/trends-developments/2017, accessed 01/05/19.
14. 10.1136/emj.2006.03460310.1136/emj.2006.034603 ↗
15. 10.2217/nnm.11.7510.2217/nnm.11.75 ↗
16. 10.1016/0736-4679(86)90219-210.1016/0736-4679(86)90219-2 ↗
17. 10.1007/bf0325993010.1007/bf03259930 ↗
18. 10.1186/1865-1380-4-6510.1186/1865-1380-4-65 ↗
19. 10.1021/jacs.8b0443510.1021/jacs.8b04435 ↗
20. 10.1002/anie.20060187810.1002/anie.200601878 ↗
21. 10.1186/1743-8977-10-910.1186/1743-8977-10-9 ↗
22. 10.1021/ja903726m10.1021/ja903726m ↗
23. 10.3390/nano710032110.3390/nano7100321 ↗
24. 10.1021/acsomega.8b0018510.1021/acsomega.8b00185 ↗
25. 10.1016/s0140-6736(68)92204-610.1016/s0140-6736(68)92204-6 ↗
26. 10.1186/s12995-016-0118-510.1186/s12995-016-0118-5 ↗
27. 10.1016/j.emc.2004.05.00410.1016/j.emc.2004.05.004 ↗
28. Suzanne Schoenfelt M.-M. E. · 2011
29. 10.1136/bmj.296.6635.150710.1136/bmj.296.6635.1507 ↗
30. Glucksman D. H. · 1974
31. 10.1038/nmat260810.1038/nmat2608 ↗
32. 10.1021/ja909271510.1021/ja9092715 ↗
33. 10.1039/c0jm02381g10.1039/c0jm02381g ↗
34. 10.1021/ja805795310.1021/ja8057953 ↗
35. 10.1021/cm102601v10.1021/cm102601v ↗
36. 10.1039/c2ce26847g10.1039/c2ce26847g ↗
37. 10.1002/jps.260066113910.1002/jps.2600661139 ↗
38. 10.3109/1556365960901376610.3109/15563659609013766 ↗
39. 10.1016/j.ajem.2005.12.02510.1016/j.ajem.2005.12.025 ↗
40. 10.1080/1556365060090714010.1080/15563650600907140 ↗
41. 10.1038/nbt.148010.1038/nbt.1480 ↗
42. Wang Z. · Yonago Acta Med. · 2011 · 54 · 11
43. Rose J. · J. Anat. · 1987 · 8 · 151
44. Ascjenbrenner D. S. · 2009
45. 10.1016/j.ijpharm.2016.08.01010.1016/j.ijpharm.2016.08.010 ↗
46. Patel J. · 2015 · 286
47. 10.1186/1743-8977-11-3010.1186/1743-8977-11-30 ↗